BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38332011)

  • 1. Development of a predictive nomogram for postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Bai J; Huang M; Zhou J; Song B; Hua J; Ding R
    Sci Rep; 2024 Feb; 14(1):3303. PubMed ID: 38332011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
    He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
    J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.
    Liang L; Li C; Wang MD; Wang H; Zhou YH; Zeng YY; Zhang WG; Chen TH; Wang NY; Li J; Zhang YM; Wang Y; Gu WM; Xing H; Diao YK; Lau WY; Zhang CW; Pawlik TM; Shen F; Huang DS; Yang T
    J Hematol Oncol; 2021 Oct; 14(1):165. PubMed ID: 34641921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors.
    Zheng X; Cao F; Qian L; Dong J
    Cancer Control; 2021; 28():10732748211038445. PubMed ID: 34569304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Xu L; Peng ZW; Chen MS; Shi M; Zhang YJ; Guo RP; Lin XJ; Lau WY
    J Hepatol; 2015 Jul; 63(1):122-30. PubMed ID: 25725438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.
    Xu JX; Qin SL; Wei HW; Chen YY; Peng YC; Qi LN
    Ann Med; 2023 Dec; 55(1):2199219. PubMed ID: 37070467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Sheng Y; Wang Q; Liu HF; Chen WH; He ZM; Wang Q
    Acad Radiol; 2023 Jul; 30(7):1288-1297. PubMed ID: 36424310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma.
    Khalaf MH; Sundaram V; AbdelRazek Mohammed MA; Shah R; Khosla A; Jackson K; Desai M; Kothary N
    Radiology; 2019 Jan; 290(1):254-261. PubMed ID: 30299233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
    Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
    Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
    Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma.
    Jiang J; Hu H; Liu R; Wang JH; Long XR; Fan J; Yan ZP
    Medicine (Baltimore); 2017 Aug; 96(32):e7390. PubMed ID: 28796032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Nomogram for Hepatitis B Virus-related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection.
    Huang J; Liu FC; Li L; Yuan SX; Yang Y; Jiang BG; Liu H; Pan ZY
    Am J Clin Oncol; 2020 Jan; 43(1):20-27. PubMed ID: 31633514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a predictive model for short-term efficacy of transcatheter arterial chemoembolization treatment in hepatocellular carcinoma and its clinical application.
    Wei J; Wang Z
    J Cancer Res Ther; 2019; 15(4):941-946. PubMed ID: 31436256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization.
    Arslan M; Degirmencioglu S
    Curr Med Imaging Rev; 2019; 15(4):380-385. PubMed ID: 31989907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study.
    Hsu CY; Liu PH; Hsia CY; Lee YH; Nagaria TS; Lee RC; Lin HC; Huo TI
    Ann Surg Oncol; 2016 Mar; 23(3):994-1002. PubMed ID: 26487000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung immune prognostic index‑based nomogram for recurrence of hepatocellular carcinoma after postoperative adjuvant TACE.
    Liang Y; Yang R; Shang J; Zhong D; Yang Q; Su Y; Shi Y; Huang X
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16461-16471. PubMed ID: 37707573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
    Liu K; Zheng X; Lu D; Tan Y; Hou C; Dai J; Shi W; Jiang B; Yao Y; Lu Y; Cao Q; Chen R; Zhang W; Xie J; Chen L; Jiang M; Zhang Z; Liu L; Liu J; Li J; Lv W; Wu X
    Radiol Med; 2024 Jan; 129(1):14-28. PubMed ID: 37863847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.